Home » Greater Flexibility May Make U.S. A Magnet for New Biosimilars
Greater Flexibility May Make U.S. A Magnet for New Biosimilars
April 6, 2012
Companies seeking to market biosimilars may have more success getting their products approved in the U.S. than in other highly regulated markets, thanks to “step-wise” guidance developed by the U.S. Food and Drug Administration (FDA) and released in February.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor